Recent Updates — BSEM

BioStem Technologies raised approximately $3 million in a private placement by selling 735,296 shares of common stock at $4.08 per share, accompanied by Series A and Series B warrants to purchase an equal number of shares at an exercise price of $3.83. The transaction closed on September 30, 2026, with proceeds designated for working capital and general corporate purposes. Additionally, the filing discloses that a $10 million clearance payment due to BioTissue Holdings following FDA approval of its Catalyze product remains unpaid as of late September 2026, with discussions ongoing regarding timing and terms. BioStem Technologies operates in the regenerative medicine industry, developing and commercializing perinatal tissue allograft products.

BioStem Technologies entered into a common stock purchase agreement with Roth Principal Investments on September 18, 2026, establishing a committed equity facility allowing the company to sell up to $40 million of its common stock. The company holds sole discretion over the timing and amount of sales, which are subject to conditions including a minimum share price threshold of $1.00 and Nasdaq listing requirements. Roth Principal Investments is obligated to purchase shares only as directed by BioStem, with pricing based on volume-weighted average prices less fixed discounts ranging from 3.0% to 5.0%. The facility includes a registration rights agreement for the resale of up to 12,050,000 shares and requires the payment of a $400,000 cash commitment fee plus reimbursement of legal expenses. BioStem Technologies operates in the regenerative medicine industry, developing and commercializing perinatal tissue allograft products.

BioStem Technologies reported second quarter 2026 net revenue of $7.9 million, a 29% sequential increase from the first quarter's $6.1 million, driven by Neox and Clarix product sales. The company raised its full-year 2026 revenue guidance to a range of $26 million to $29 million, up from the previous upper bound of $25 million. GAAP net loss widened to $9.0 million, or $0.52 per share, compared to a near-breakeven result in the prior year period, as operating expenses rose to $13.2 million due to commercial expansion. BioStem also completed a $2.5 million private placement with its first institutional investor and uplisted its common stock to the Nasdaq Capital Market on August 7, 2026. The company operates in the regenerative medicine industry, developing, manufacturing, and commercializing perinatal tissue allograft products.